Observational studyNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2026
The real-world effectiveness and safety of off-label rituximab in a large cohort of Middle Eastern multiple sclerosis patients.
Observational study in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rituximab (RTX) is increasingly used off-label for the treatment of multiple sclerosis (MS), yet real-world evidence from Middle Eastern populations remains limited. This multicenter, retrospective observational study evaluated the effectiveness and safety of RTX using data from the MENACTRIMS registry across seven Middle Eastern countries (Iraq, Kuwait, Lebanon, Oman, Saudi Arabia, Tunisia, and the United Arab Emirates). A total of 774 MS patients were included: 482 with relapsing-remitting MS (RRMS) and 292 with active secondary progressive MS (aSPMS). Patients received intravenous RTX at doses of 500 mg or 1000 mg every 6-12 months. The cohort was predominantly female (72.1%), with a mean age of 39.6 years and a mean disease duration of 11.9 years from symptom onset. RTX treatment was associated with a significant reduction in annualized relapse rate (ARR), decreasing from 1.65 to 0.08 in RRMS and from 2.03 to 0.02 in aSPMS (p < 0.001). Expanded Disability Status Scale (EDSS) scores remained stable in RRMS but increased by 1.0 point in aSPMS (p < 0.001). MRI activity was suppressed in most RRMS patients, with 89.1% showing no new or enlarging lesions, whereas only 8.1% of aSPMS patients demonstrated similar stability. NEDA-3 was achieved in 47.3% of RRMS patients. A total of 491 adverse events were reported, predominantly mild infusion-related reactions (92.5%). Overall, off-label RTX demonstrated substantial real-world effectiveness and a favorable safety profile in Middle Eastern MS patients, particularly in RRMS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.